As India continues to prioritise preventive healthcare and universal immunisation, a seemingly technical GST classification issue concerning vaccines has assumed considerable significance. Under Customs law, Vaccines have always been classified as ‘vaccines for human medicine’ or ‘vaccines for veterinary medicine’ However, the issue lies in GST rate classification wherein Entry 174 of Schedule I to Notification No. 1/2017-Central Tax (Rate), prescribes GST at 5 per cent for “Animal or Human Blood Vaccines” falling under Heading 3002.
While the intention behind granting a concessional rate for vaccines appears clear, the language used in the notification has given rise to interpretational uncertainty.
The expression “Animal or Human Blood Vaccines” is not a recognised category in medical science or pharmaceutical trade parlance. Consequently, questions have arisen regarding the scope of the entry and the GST rate applicable to vaccines.
Importantly, this ambiguity is not a recent development. As early as March 2018, the CGST authorities formally brought the issue to the attention of the GST Fitment Committee. The communication acknowledged the possibility of multiple interpretations of the entry and specifically recommended issuance of a clarification to avoid confusion among taxpayers and tax authorities. The Commissionerate further observed that such a clarification would greatly assist both trade and field formations. Despite the issue having been highlighted more than eight years ago, no definitive clarification has been issued. The resulting uncertainty has compelled taxpayers to adopt varying positions, thereby creating the very inconsistency that the GST framework sought to eliminate.
The issue has also come under judicial consideration. In a recent writ petition before the Hon’ble Bombay High Court, it was contended that there is no identifiable product known as “Animal or Human Blood Vaccines” and that the wording of the notification has given rise to avoidable interpretational concerns. The Court found prima facie substance in the contention and has since referred the same to the Ministry of Finance for consideration.
The significance of this issue extends beyond tax classification. Vaccines are essential public health products that play a critical role in disease prevention. Uncertainty regarding their tax treatment can lead to can result in interpretational disputes, increased compliance costs and avoidable litigation. A clear policy position would benefit both industry and tax administration while supporting the Government’s broader healthcare objectives. Given the long standing nature of the issue, stakeholders had expected greater clarity through the GST Council’s deliberations. With the council’s meeting now scheduled for 7th October the industry must wait a little longer for clarity. While the postponement provides additional time for deliberation, it also presents an opportunity for the Council to comprehensively resolve a dispute that has remained pending since the inception of GST.
The solution itself need not be complicated. A simple clarification explaining the intended scope would bring much needed certainty, reduce litigation and ensure uniform tax treatment across the sector. Varying interpretations of the relevant entry by GST authorities have given rise to multiple ongoing investigations.
More importantly, it would reaffirm the GST Council’s commitment to fostering a predictable and taxpayer-friendly indirect tax regime. It would strengthen confidence in the GST framework and demonstrate that genuine interpretational concerns can be addressed through timely and responsive policymaking rather than prolonged litigation.